Zacks: Brokerages Expect Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.18 EPS
Brokerages forecast that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will post ($0.18) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.17). Achillion Pharmaceuticals reported earnings of ($0.15) per share in the same quarter last year, which would indicate a negative year over year growth rate of 20%. The company is expected to issue its next earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.65) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.57). For the next financial year, analysts expect that the firm will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.82) to ($0.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). During the same period last year, the company posted ($0.14) earnings per share.
A number of research firms have recently commented on ACHN. BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Robert W. Baird downgraded Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a report on Thursday, August 10th. Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, Chardan Capital dropped their price objective on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. Achillion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $6.75.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded down 2.219% during midday trading on Wednesday, reaching $3.745. The company’s stock had a trading volume of 1,168,789 shares. Achillion Pharmaceuticals has a 12-month low of $3.15 and a 12-month high of $6.87. The company’s market cap is $512.17 million. The stock’s 50-day moving average price is $4.31 and its 200-day moving average price is $4.27.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. boosted its position in shares of Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 800 shares during the period. SG Americas Securities LLC lifted its position in Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 4,144 shares during the period. TradeLink Capital LLC acquired a new stake in Achillion Pharmaceuticals during the 2nd quarter worth approximately $132,000. Highbridge Capital Management LLC acquired a new stake in Achillion Pharmaceuticals during the 1st quarter worth approximately $149,000. Finally, Legal & General Group Plc lifted its position in Achillion Pharmaceuticals by 53.8% during the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after acquiring an additional 15,000 shares during the period. 74.57% of the stock is owned by hedge funds and other institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.